Dr. Naval Daver is a Professor , Co-Section Head of AML, and Sirector of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a world renowned clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and MDS, and has served as principal investigator on more than 100 institutional, national, and international clinical trials in these diseases, including multiple registrational trials.

These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. Dr Daver has published more than 500 peer-reviewed manuscripts and is on the editorial board of numerous hematology-oncology journals. He is a renowned educator and serves as Chair on numerous international meetings. He also is a key mentor to numerous fellows and junior faculty in the Department of Leukemia.